Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Other Non-Current Assets (2022 - 2025)

Historic Other Non-Current Assets for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to $1.6 million.

  • Centessa Pharmaceuticals' Other Non-Current Assets fell 2877.63% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 2877.63%. This contributed to the annual value of $2.0 million for FY2024, which is 1989.04% down from last year.
  • Per Centessa Pharmaceuticals' latest filing, its Other Non-Current Assets stood at $1.6 million for Q3 2025, which was down 2877.63% from $1.7 million recorded in Q2 2025.
  • Over the past 5 years, Centessa Pharmaceuticals' Other Non-Current Assets peaked at $6.0 million during Q1 2023, and registered a low of $619000.0 during Q1 2022.
  • Over the past 4 years, Centessa Pharmaceuticals' median Other Non-Current Assets value was $1.9 million (recorded in 2024), while the average stood at $2.1 million.
  • In the last 5 years, Centessa Pharmaceuticals' Other Non-Current Assets surged by 87576.74% in 2023 and then tumbled by 6882.45% in 2024.
  • Centessa Pharmaceuticals' Other Non-Current Assets (Quarter) stood at $1.9 million in 2022, then skyrocketed by 35.85% to $2.6 million in 2023, then fell by 19.89% to $2.0 million in 2024, then decreased by 22.34% to $1.6 million in 2025.
  • Its Other Non-Current Assets was $1.6 million in Q3 2025, compared to $1.7 million in Q2 2025 and $1.9 million in Q1 2025.